PharmaTher submits FDA Orphan Drug and Rare Pediatric Disease designation applications for 3D-printed creatine monohydrate

PharmaTher Holdings announced it submitted applications for Orphan Drug Designation and Rare Pediatric Disease Designation to the FDA for its 3D-printed creatine monohydrate product, which uses 3D-printing to create weight-banded, taste-masked, dissolvable tablets for precise dosing in children.

Detected & updated continuously · Source: Nebula